前海健康(00911.HK) 预计,截至2024年12月31日止年度纯利约130万元,跟2023年度录得约5,270万元亏损相比,实现转亏为盈。原因包括2023年度的毛损转为本年度毛利,约2,970万元,处置子公司获得约5,190万元的一次性收益;及抵销因电子元件产品的市场价格在2024年最后一季度下降,以致集团计提约5,400万元的亏损合约拨备。(ha/j)(港股报价延迟最少十五分钟。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/08/22 | 中期业绩 | 无派息 |
2024/04/17 | 特别业绩 | 合并:10股合并为1股 |
2024/03/14 | 末期业绩 | 无派息 |
2023/08/22 | 中期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.